4.7 Article

Analysis of the Bacterial Communities Present in Lungs of Patients with Cystic Fibrosis from American and British Centers

期刊

JOURNAL OF CLINICAL MICROBIOLOGY
卷 49, 期 1, 页码 281-291

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.01650-10

关键词

-

资金

  1. Anna Trust
  2. National Institutes of Health [HL092964]
  3. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092964] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The aim of this study was to determine whether geographical differences impact the composition of bacterial communities present in the airways of cystic fibrosis (CF) patients attending CF centers in the United States or United Kingdom. Thirty-eight patients were matched on the basis of clinical parameters into 19 pairs comprised of one U. S. and one United Kingdom patient. Analysis was performed to determine what, if any, bacterial correlates could be identified. Two culture-independent strategies were used: terminal restriction fragment length polymorphism (T-RFLP) profiling and 16S rRNA clone sequencing. Overall, 73 different terminal restriction fragment lengths were detected, ranging from 2 to 10 for U. S. and 2 to 15 for United Kingdom patients. The statistical analysis of T-RFLP data indicated that patient pairing was successful and revealed substantial transatlantic similarities in the bacterial communities. A small number of bands was present in the vast majority of patients in both locations, indicating that these are species common to the CF lung. Clone sequence analysis also revealed that a number of species not traditionally associated with the CF lung were present in both sample groups. The species number per sample was similar, but differences in species presence were observed between sample groups. Cluster analysis revealed geographical differences in bacterial presence and relative species abundance. Overall, the U.S. samples showed tighter clustering with each other compared to that of United Kingdom samples, which may reflect the lower diversity detected in the U.S. sample group. The impact of cross-infection and biogeography is considered, and the implications for treating CF lung infections also are discussed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of single breath hyperpolarized129Xe MRI with dynamic19F MRI in cystic fibrosis lung disease

Andrew McCallister, Sang Hun Chung, Michael Antonacci, Margret Z. Powell, Agathe S. Ceppe, Scott H. Donaldson, Yueh Z. Lee, Rosa Tamara Branca, Jennifer L. Goralski

Summary: In CF subjects, ventilation abnormalities can be identified by both (19)F and (HPXe)-Xe-129 imaging, but these abnormalities are not entirely congruent. (19)F and (HPXe)-Xe-129 imaging provide complementary information that allows for differentiation of normally ventilated, slowly ventilated, and non-ventilated regions in the lungs.

MAGNETIC RESONANCE IN MEDICINE (2021)

Review Respiratory System

PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy

Dave P. Nichols, Scott H. Donaldson, Carla A. Frederick, Steven D. Freedman, Daniel Gelfond, Lucas R. Hoffman, Andrea Kelly, Michael R. Narkewicz, Jessica E. Pittman, Felix Ratjen, Scott D. Sagel, Margaret Rosenfeld, Sarah Jane Schwarzenberg, Pradeep K. Singh, George M. Solomon, Michael S. Stalvey, Shannon Kirby, Jill M. VanDalfsen, John P. Clancy, Steven M. Rowe

Summary: Highly effective CFTR modulator drug therapy is increasingly available for cystic fibrosis patients, with multiple observational research studies underway to better understand its impacts. The PROMISE study focuses on the broad impacts of starting elexacaftor/tezacaftor/ivacaftor in the US population, aiming to address important health outcomes, clinical care priorities, and research needs.

JOURNAL OF CYSTIC FIBROSIS (2021)

Article Respiratory System

Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease

Charlotte Rigauts, Juliana Aizawa, Steven L. Taylor, Geraint B. Rogers, Matthias Govaerts, Paul Cos, Lisa Ostyn, Sarah Sims, Eva Vandeplassche, Mozes Sze, Yves Dondelinger, Lars Vereecke, Heleen Van Acker, Jodie L. Simpson, Lucy Burr, Anne Willems, Michael M. Tunney, Cristina Cigana, Alessandra Bragonzi, Tom Coenye, Aurelie Crabbe

Summary: The presence of Rothia mucilaginosa in the lower airways has an inhibitory effect on pathogen-induced inflammation and is negatively correlated with pro-inflammatory markers in bronchiectasis patients. Mechanistically, R. mucilaginosa inhibits inflammation by reducing NF-kappa B pathway activation. These findings suggest that R. mucilaginosa in the lower airways could potentially mitigate inflammation and impact the severity and progression of chronic respiratory disorders.

EUROPEAN RESPIRATORY JOURNAL (2022)

Article Respiratory System

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study

Scott H. Donaldson, Beth L. Laube, Peter Mogayzel, Timothy E. Corcoran, Joseph M. Pilewski, Agathe Ceppe, Jihong Wu, Pradeep G. Bhambhvani, Felix Ratjen, Scott D. Sagel, J. P. Clancy, Steven M. Rowe, William D. Bennett

Summary: This observational study investigated the effect of lumacaftor-ivacaftor on mucociliary and cough clearance in CF patients. The results showed no effect on whole lung mucociliary clearance, but cough-assisted clearance was significantly increased. Sweat chloride improved, indicating a modest restoration of CFTR activity, but there was no demonstrable change in lung function indices. The authors speculate that the modest effect of lumacaftor-ivacaftor on CFTR function was insufficient to improve mucociliary clearance.

JOURNAL OF CYSTIC FIBROSIS (2022)

Article Respiratory System

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis

Cecilia Kristensson, Annika Astrand, Scott Donaldson, Ron Goldwater, Raolat Abdulai, Naimish Patel, Philip Gardiner, Ulrika Tehler, Anne-Kristina Mercier, Marita Olsson, Eva Ersdal, Jukka Maenpaa, Tobias Bramer, Anna Malmgren, William Bennett, Christina Keen

Summary: AZD5634 demonstrated favorable pharmacokinetics and safety in both healthy subjects and patients with CF, although proof of mechanism was not achieved in patients with CF.

JOURNAL OF CYSTIC FIBROSIS (2022)

Review Biochemistry & Molecular Biology

The gut microbiome and mental health: advances in research and emerging priorities

Andrew P. Shoubridge, Jocelyn M. Choo, Alyce M. Martin, Damien J. Keating, Ma-Li Wong, Julio Licinio, Geraint B. Rogers

Summary: The gut microbiome has a significant influence on human neurophysiology and mental health, playing a role in the development of psychiatric conditions and the effectiveness of common therapies. With an increasing acceptance of its role, research is now shifting towards using this knowledge to improve clinical outcomes and understanding the mechanisms of gut microbiome-brain interactions.

MOLECULAR PSYCHIATRY (2022)

Article Pharmacology & Pharmacy

Current state of CFTR modulators for treatment of Cystic Fibrosis Katherine A. Despotes and Scott H. Donaldson

Katherine A. Despotes, Scott H. Donaldson

Summary: Small molecular modulators have transformed the care of cystic fibrosis patients, improving lung function, respiratory symptoms, and nutrition. Efforts are being made to expand these therapies to more pediatric patients. Alternative approaches are needed for those with ineligible mutations.

CURRENT OPINION IN PHARMACOLOGY (2022)

Article Respiratory System

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Sarah Jane Schwarzenberg, Phuong T. Vu, Michelle Skalland, Lucas R. Hoffman, Christopher Pope, Daniel Gelfond, Michael R. Narkewicz, David P. Nichols, Sonya L. Heltshe, Scott H. Donaldson, Carla A. Frederick, Andrea Kelly, Jessica E. Pittman, Felix Ratjen, Margaret Rosenfeld, Scott D. Sagel, George M. Solomon, Michael S. Stalvey, John P. Clancy, Steven M. Rowe, Steven D. Freedman

Summary: The study aims to investigate the effect of ETI on gastrointestinal symptoms in patients with cystic fibrosis. The results show that there was an overall improvement in gastrointestinal symptoms after 6 months of ETI treatment.

JOURNAL OF CYSTIC FIBROSIS (2023)

Article Medicine, General & Internal

The Development of Schematics to Illustrate Women's Experiences with Adjuvant Hormone Therapy in the Treatment of Breast Cancer

Othman AlOmeir, Nilesh Patel, Parastou Donyai

Summary: The objective of this study was to visually represent women's experiences with oral hormone therapy for breast cancer using data synthesized in the literature. Three schematics were drawn and validated through interviews with healthcare professionals and breast cancer survivors. The final schematics could aid patient-professional communication and support decisions regarding hormone medication in breast cancer.

PATIENT PREFERENCE AND ADHERENCE (2022)

Article Oncology

Hobson's choice or a horned dilemma: a grounded theory on adherence to adjuvant endocrine therapy verified with breast cancer survivors

Othman AlOmeir, Nilesh Patel, Parastou Donyai

Summary: The study developed a grounded theory based on a literature review and meta-synthesis of qualitative research to explain the difficulties faced by breast cancer survivors in making the initial decision to accept long-term endocrine therapy and the challenges of continuing or stopping treatment. The findings indicated that some women changed their minds about treatment due to medication side effects over time.

SUPPORTIVE CARE IN CANCER (2022)

Article Health Care Sciences & Services

News Media Coverage of the Problem of Purchasing Fake Prescription Medicines on the Internet: Thematic Analysis

Hamzeh Almomani, Nilesh Patel, Parastou Donyai

Summary: More people are purchasing prescription medicines from internet pharmacies, which carries the risk of buying fake medicines. This study explores how newspapers cover this issue and highlights the complexity of personal beliefs and external circumstances that influence these purchases.

JMIR FORMATIVE RESEARCH (2023)

Article Health Care Sciences & Services

Reasons That Lead People to End Up Buying Fake Medicines on the Internet: Qualitative Interview Study

Hamzeh Almomani, Nilesh Patel, Parastou Donyai

Summary: This study aimed to identify why people in the United Kingdom purchase prescription-only medicines (POMs) from the internet and their perceptions of risks associated with fake medicines. The factors influencing the decision to buy POMs online were grouped into themes, including advantages, disadvantages, social influencing factors, barriers, and facilitators. The findings could inform the development of public awareness campaigns and interventions to minimize the purchase of POMs online.

JMIR FORMATIVE RESEARCH (2023)

Editorial Material Respiratory System

More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice

Scott H. Donaldson

Summary: Higher concentrations of hypertonic saline provide better protection against pulmonary exacerbation and respiratory symptom improvement in cystic fibrosis patients, and are generally well tolerated when delivered with rapid nebulizer systems.

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Pharmacology & Pharmacy

Exploring Drug Shortages in the United Kingdom

Mohamed Obiedalla, Nilesh Patel, Parastou Donyai

Summary: Drug shortages have a negative impact on patients and pharmacists, and need to be addressed. The survey revealed that the majority of pharmacists experience drug shortages on a weekly basis, and these shortages increase their workload and potentially affect the quality of patient care.

PHARMACY (2023)

Article Respiratory System

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis The SIMPLIFY Clinical Trial Study Design

Nicole Mayer-Hamblett, David P. Nichols, Katherine Odem-Davis, Kristin A. Riekert, Greg S. Sawicki, Scott H. Donaldson, Felix Ratjen, Michael W. Konstan, Noah Simon, Daniel B. Rosenbluth, George Retsch-Bogart, John P. Clancy, Jill M. VanDalfsen, Rachael Buckingham, Alex H. Gifford

Summary: The study aims to evaluate whether the daily treatment burden can be reduced for individuals with cystic fibrosis receiving new triple-combination therapy, by comparing the effects of discontinuing versus continuing two commonly used chronic therapies.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)

暂无数据